Michele Fiscella

Michele Fiscella

Auto-generated profile, based on publicly available information

Michele Fiscella

REGENXBIO Inc., 9804 Medical Center Drive, Rockville, MD, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
NBNicholas Buss
Nicholas Buss
LLLisa Lanigan
Lisa Lanigan
JZJillynne Zeller
Jillynne Zeller
DCDerek Cissell
Derek Cissell
MMMonica Metea
Monica Metea
MFMichele Fiscella
Michele Fiscella
Recent studies in non-human primates administered recombinant adeno-associated viruses (rAAVs) have shown lesions in the dorsal root ganglia (DRG) of unknown pathogenesis. In this study, rAAV9s manufactured using different purification methods alongside a non-expressing Null AAV9 vector was administered to groups of cynomolgus monkeys followed by neuropathological evaluation after 4 weeks. Lesions, including neuronal degeneration, increased cellularity, and nerve fiber degeneration, were observed in the DRG, regardless of purification methods. Animals did not develop any neurological signs throughout the study, and there was no loss of function observed in neuro-electrophysiological endpoints or clear effects on intraepidermal nerve fiber density. However, magnetic resonance imaging (MRI) of animals with axonopathy showed an increase in short tau inversion recovery (STIR) intensity and decrease in fractional anisotropy. In animals administered the Null AAV9 vector, DRG lesions were not observed despite vector DNA being detected in the DRG at levels equivalent to or greater than rAAV9-treated animals. This study further supports that DRG toxicity is associated with transgene overexpression in DRGs, with particular sensitivity at the lumbar and lumbosacral level. The data from this study also showed that the nerve fiber degeneration did not correlate with any functional effect on nerve conduction but was detectable by MRI.

6 January 2020 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
BGBoris Gorovits
Boris Gorovits
MFMichele Fiscella
Michele Fiscella
MHMike Havert
Mike Havert
EKEugen Koren
Eugen Koren
BLBrian Long
Brian Long
SPShobha Purushothama
Shobha Purushothama

5 January 2026 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
BGBoris Gorovits
Boris Gorovits
MAMitra Azadeh
Mitra Azadeh
MFMichele Fiscella
Michele Fiscella
THTravis Harrison
Travis Harrison
MHMagdalena Hofer
Magdalena Hofer
AZAn Zhao
An Zhao

12 March 2026 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
LOLawrence Owusu
Lawrence Owusu
SKSunJung Kim
SunJung Kim
HPHiren Patel
Hiren Patel
SFSteven Foltz
Steven Foltz
GCGary N.Y. Chan
Gary N.Y. Chan
MFMichele Fiscella
Michele Fiscella
Use of adeno-associated virus (AAV)-mediated transfer of functional microdystrophins to address Duchenne muscular dystrophy (DMD) has been established. RGX-202, an AAV8 vector encoding a novel, optimized human microdystrophin with an extended C-terminal domain, expressed under the Spc5-12 muscle-specific promoter, was evaluated for tolerability and efficacy in dystrophin-deficient mdx mouse in 12- and 26-week studies at vector doses ranging from 3 × 1013 to 5 × 1014 gc/kg. A single intravenous administration of RGX-202 was well tolerated and led to robust, dose-dependent expression of microdystrophin in skeletal and cardiac muscles at 12 weeks, which persisted to 26 weeks post-administration. Increased microdystrophin was associated with recruitment of the dystrophin-associated protein complex to the sarcolemma, particularly at doses ≥1 × 1014 gc/kg. Histologic and magnetic resonance imaging examinations revealed marked and sustained suppression of dystrophic pathology in all RGX-202-treated mice. Functionally, gains were observed in the in vitro specific force of extensor digitorum longus muscle, in vivo grip strength, and the rescue of treadmill and gait deficits. These findings provide preclinical evidence for the therapeutic efficacy of RGX-202 at a minimum effective dose (MED) of 1 × 1014 gc/kg in the murine DMD model. This MED served as the starting dose for the RGX-202 clinical study (NCT05693142), which has currently completed phase III enrollment.